vs
Side-by-side financial comparison of Carlyle Group Inc. (CG) and Dexcom (DXCM). Click either name above to swap in a different company.
Carlyle Group Inc. is the larger business by last-quarter revenue ($1.9B vs $1.3B, roughly 1.5× Dexcom). Dexcom runs the higher net margin — 21.2% vs 18.8%, a 2.4% gap on every dollar of revenue. On growth, Carlyle Group Inc. posted the faster year-over-year revenue change (84.1% vs 21.6%). Over the past eight quarters, Carlyle Group Inc.'s revenue compounded faster (66.2% CAGR vs 12.0%).
The Carlyle Group Inc. is an American multinational company with operations in private equity, alternative asset management and financial services. As of 2023, the company had $426 billion of assets under management.
Dexcom, Inc. is an American multinational healthcare company that develops, manufactures, produces and distributes a line of continuous glucose monitoring (CGM) systems for diabetes management. It operates internationally with global headquarters and R&D center in San Diego, California, U.S.A. and manufacturing facilities in Mesa, Arizona, U.S.A.; Batu Kawan, Malaysia and Athenry, County Galway, Ireland.
CG vs DXCM — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $1.9B | $1.3B |
| Net Profit | $358.1M | $267.3M |
| Gross Margin | — | 62.9% |
| Operating Margin | 24.3% | 25.6% |
| Net Margin | 18.8% | 21.2% |
| Revenue YoY | 84.1% | 21.6% |
| Net Profit YoY | 69.8% | 153.6% |
| EPS (diluted) | $0.96 | $0.67 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $1.3B | ||
| Q4 25 | $1.9B | $1.3B | ||
| Q3 25 | $332.7M | $1.2B | ||
| Q2 25 | $1.6B | $1.2B | ||
| Q1 25 | $973.1M | $1.0B | ||
| Q4 24 | $1.0B | $1.1B | ||
| Q3 24 | $2.6B | $994.2M | ||
| Q2 24 | $1.1B | $1.0B |
| Q1 26 | — | $267.3M | ||
| Q4 25 | $358.1M | $267.3M | ||
| Q3 25 | $900.0K | $283.8M | ||
| Q2 25 | $319.7M | $179.8M | ||
| Q1 25 | $130.0M | $105.4M | ||
| Q4 24 | $210.9M | $151.7M | ||
| Q3 24 | $595.7M | $134.6M | ||
| Q2 24 | $148.2M | $143.5M |
| Q1 26 | — | 62.9% | ||
| Q4 25 | — | 62.9% | ||
| Q3 25 | — | 60.5% | ||
| Q2 25 | — | 59.5% | ||
| Q1 25 | — | 56.9% | ||
| Q4 24 | — | 58.9% | ||
| Q3 24 | — | 59.7% | ||
| Q2 24 | — | 62.4% |
| Q1 26 | — | 25.6% | ||
| Q4 25 | 24.3% | 25.6% | ||
| Q3 25 | 25.8% | 20.1% | ||
| Q2 25 | 28.0% | 18.4% | ||
| Q1 25 | 17.6% | 12.9% | ||
| Q4 24 | 25.7% | 17.0% | ||
| Q3 24 | 29.9% | 15.3% | ||
| Q2 24 | 20.5% | 15.7% |
| Q1 26 | — | 21.2% | ||
| Q4 25 | 18.8% | 21.2% | ||
| Q3 25 | 0.3% | 23.5% | ||
| Q2 25 | 20.3% | 15.5% | ||
| Q1 25 | 13.4% | 10.2% | ||
| Q4 24 | 20.4% | 13.6% | ||
| Q3 24 | 22.6% | 13.5% | ||
| Q2 24 | 13.9% | 14.3% |
| Q1 26 | — | $0.67 | ||
| Q4 25 | $0.96 | $0.67 | ||
| Q3 25 | $0.00 | $0.70 | ||
| Q2 25 | $0.87 | $0.45 | ||
| Q1 25 | $0.35 | $0.27 | ||
| Q4 24 | $0.56 | $0.37 | ||
| Q3 24 | $1.63 | $0.34 | ||
| Q2 24 | $0.40 | $0.35 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $2.0B | $917.7M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $7.1B | $2.7B |
| Total Assets | $29.1B | $6.3B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $917.7M | ||
| Q4 25 | $2.0B | $917.7M | ||
| Q3 25 | $2.2B | $1.8B | ||
| Q2 25 | $1.3B | $1.2B | ||
| Q1 25 | $1.2B | $904.9M | ||
| Q4 24 | $1.3B | $606.1M | ||
| Q3 24 | $1.4B | $621.2M | ||
| Q2 24 | $914.8M | $939.2M |
| Q1 26 | — | $2.7B | ||
| Q4 25 | $7.1B | $2.7B | ||
| Q3 25 | $6.8B | $2.7B | ||
| Q2 25 | $6.7B | $2.6B | ||
| Q1 25 | $6.4B | $2.3B | ||
| Q4 24 | $6.3B | $2.1B | ||
| Q3 24 | $6.3B | $2.0B | ||
| Q2 24 | $5.7B | $2.4B |
| Q1 26 | — | $6.3B | ||
| Q4 25 | $29.1B | $6.3B | ||
| Q3 25 | $27.1B | $7.5B | ||
| Q2 25 | $25.1B | $7.3B | ||
| Q1 25 | $24.1B | $6.8B | ||
| Q4 24 | $23.1B | $6.5B | ||
| Q3 24 | $22.7B | $6.4B | ||
| Q2 24 | $22.3B | $6.8B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-1.2B | — |
| Free Cash FlowOCF − Capex | $-1.2B | — |
| FCF MarginFCF / Revenue | -65.1% | — |
| Capex IntensityCapex / Revenue | 2.2% | — |
| Cash ConversionOCF / Net Profit | -3.34× | — |
| TTM Free Cash FlowTrailing 4 quarters | $-3.4B | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $-1.2B | $294.0M | ||
| Q3 25 | $-1.6B | $659.9M | ||
| Q2 25 | $-168.8M | $303.0M | ||
| Q1 25 | $-352.1M | $183.8M | ||
| Q4 24 | $-352.8M | $301.4M | ||
| Q3 24 | $791.9M | $199.5M | ||
| Q2 24 | $-1.3B | $279.4M |
| Q1 26 | — | — | ||
| Q4 25 | $-1.2B | $192.1M | ||
| Q3 25 | $-1.6B | $579.4M | ||
| Q2 25 | $-186.3M | $208.9M | ||
| Q1 25 | $-368.8M | $96.8M | ||
| Q4 24 | $-379.5M | $176.8M | ||
| Q3 24 | $772.8M | $88.3M | ||
| Q2 24 | $-1.3B | $213.3M |
| Q1 26 | — | — | ||
| Q4 25 | -65.1% | 15.3% | ||
| Q3 25 | -475.7% | 47.9% | ||
| Q2 25 | -11.8% | 18.1% | ||
| Q1 25 | -37.9% | 9.3% | ||
| Q4 24 | -36.8% | 15.9% | ||
| Q3 24 | 29.3% | 8.9% | ||
| Q2 24 | -120.4% | 21.2% |
| Q1 26 | — | — | ||
| Q4 25 | 2.2% | 8.1% | ||
| Q3 25 | 7.0% | 6.7% | ||
| Q2 25 | 1.1% | 8.1% | ||
| Q1 25 | 1.7% | 8.4% | ||
| Q4 24 | 2.6% | 11.2% | ||
| Q3 24 | 0.7% | 11.2% | ||
| Q2 24 | 1.7% | 6.6% |
| Q1 26 | — | — | ||
| Q4 25 | -3.34× | 1.10× | ||
| Q3 25 | -1732.78× | 2.33× | ||
| Q2 25 | -0.53× | 1.69× | ||
| Q1 25 | -2.71× | 1.74× | ||
| Q4 24 | -1.67× | 1.99× | ||
| Q3 24 | 1.33× | 1.48× | ||
| Q2 24 | -8.57× | 1.95× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CG
| Fund Management Fee | $606.8M | 32% |
| Other | $528.7M | 28% |
| Global Private Equity Segment | $307.3M | 16% |
| Global Credit Segment | $238.0M | 13% |
| Carlyle Alp Invest Segment | $124.6M | 7% |
| Incentive Fee | $55.4M | 3% |
| Fee Related Performance Revenues | $29.2M | 2% |
| Investment Advice | $11.1M | 1% |
DXCM
Segment breakdown not available.
